Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

OBJECTIVES. This study examined the effects of concurrent diuretic therapy on the hemodynamic responses to short-term and sustained therapy with transdermal nitroglycerin. BACKGROUND. Sodium retention and plasma volume expansion occur during therapy with nitroglycerin and may play a role in the loss of nitroglycerin effects during sustained therapy. METHODS. Twenty-two normal male volunteers were treated for 1 week with either hydrochlorothiazide and amiloride (50 + 5 mg) (n = 11) or placebo (n = 11) in a randomized, double-blind fashion. All 22 subjects then received continuous transdermal nitroglycerin (19 +/- 1 mg/24 h) for 5 to 7 days. RESULTS. On the first and last day of transdermal nitroglycerin therapy, standing heart rate, systolic blood pressure and hematocrit values were assessed at 8, 9 and 10 AM and 12 noon. Heart rate and blood pressure responses to sublingual nitroglycerin (0.6 mg) were also evaluated before and after sustained transdermal nitroglycerin therapy. A significant loss of the hemodynamic effects of transdermal and sublingual nitroglycerin occurred during sustained therapy in both the diuretic and placebo therapy groups. In both groups, transdermal nitroglycerin therapy was associated with a significant decrease in hematocrit that persisted for the entire treatment period. CONCLUSIONS. These results suggest that diuretic therapy does not prevent plasma volume expansion or the loss of hemodynamic effects during sustained transdermal nitroglycerin therapy. The persistent decrease in hematocrit suggests that plasma volume expansion plays a role in the attenuation of nitrate effects. It also provides evidence of continued vascular activity of nitroglycerin despite loss of systemic hemodynamic effects.

This article has been cited by other articles:

				T. Gori and J. D. Parker Nitrate Tolerance: A Unifying Hypothesis Circulation, November 5, 2002; 106(19): 2510 - 2513. [Full Text] [PDF]

				J. O. Parker, J. D. Parker, R. W. Caldwell, B. Farrell, and W. H. Kaesemeyer The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy J. Am. Coll. Cardiol., April 3, 2002; 39(7): 1199 - 1203. [Abstract] [Full Text] [PDF]

				H. Watanabe, M. Kakihana, S. Ohtsuka, and Y. Sugishita Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Vitamin E on Attenuation of the Development of Nitrate Tolerance Circulation, October 21, 1997; 96(8): 2545 - 2550. [Abstract] [Full Text]

				D. Hebert, J.-X. Xiang, and J. Y.T. Lam Persistent Inhibition of Platelets During Continuous Nitroglycerin Therapy Despite Hemodynamic Tolerance Circulation, March 4, 1997; 95(5): 1308 - 1313. [Abstract] [Full Text]

				J. D. Parker, A. B. Parker, B. Farrell, and J. O. Parker The Effect of Hydralazine on the Development of Tolerance to Continuous Nitroglycerin J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 866 - 875. [Abstract] [Full Text]

				J. D. Parker, A. B. Parker, B. Farrell, and J. O. Parker Effects of Diuretic Therapy on the Development of Tolerance to Nitroglycerin and Exercise Capacity in Patients With Chronic Stable Angina Circulation, February 15, 1996; 93(4): 691 - 696. [Abstract] [Full Text]

				J. Abrams The Role of Nitrates in Coronary Heart Disease Arch Intern Med, February 27, 1995; 155(4): 357 - 364. [Abstract] [PDF]

				J. D. Parker, A. B. Parker, B. Farrell, and J. O. Parker Intermittent Transdermal Nitroglycerin Therapy : Decreased Anginal Threshold During the Nitrate-Free Interval Circulation, February 15, 1995; 91(4): 973 - 978. [Abstract] [Full Text]